American and European health agencies are investigating the role of Gilenya , the first approved pill for treating multiple sclerosis.

Multiple sclerosis is notorious for doing damage to the brain's ability to communicate with the rest of the body. But what creates the decline in mental clarity that some patients experience?

Multiple sclerosis does its damage in a patient's brain, and that's where most drugs are targeted. But one drug holds the dangerous risk of a severe brain infection for some patients.

Multiple sclerosis is generally thought of as an adult's disease. But symptoms can strike as early as childhood, a condition known as pediatric multiple sclerosis.

One of multiple sclerosis' hallmarks are lesions in the brain. They're blamed for causing chronic and worsening disability. But a new finding suggests that's not the full picture.

One of the frustrating symptoms of multiple sclerosis (MS) is cognitive decline. Many patients have trouble with concentration, judgment and memory. Researchers wanted to learn if a drug that's effective with early dementia may help MS patients.

Gilenya , a FDA-approved multiple sclerosis drug, had positive results in a late-stage clinical trial. The results may help ease safety concerns about the drug.

What causes multiple sclerosis? There's been a lot of speculation, but few definitive answers. Researchers now believe they've found a troublesome gene that may cause MS in some patients.

A new medication for multiple sclerosis just got one step closer to being available for use. Researchers have published data that they believe shows exactly how the drug works in the brain.

Multiple sclerosis manifests in a wide range of symptoms, from difficulty with balance to fatigue and vision problems. These problems all originate in the brain, but how?